Navigation Links
Drug Surveillance System Needs to Be Fixed

The current drug surveillance system needs to be fixed, argues an editorial in this weeks BMJ.

The call follows a recent analysis of the diabetes drug rosiglitazone (Avandia) which raised serious questions about the drugs safety.

Rosiglitazone was approved by the US Food and Drug Administration (FDA) in 1999 and by the European Medicines Agency (EMEA) in 2000. Its popularity has increased steadily, with more than one million prescriptions written in the one year period ending March 2006 in England alone.

But last month an analysis of 42 trials of rosiglitazone, published in the New England Journal of Medicine, found that the drug was associated with an increased risk of heart attack and death from cardiovascular causes.

These emerging safety concerns highlight the need for a better system of drug evaluation both before and after approval, says Dr Dhruv Kazi from the London School of Economics.

He argues that the current approach relies heavily on passive surveillance and is based on reports of unusual adverse events from consumers, practitioners, manufacturers, and national regulatory authorities. Alternatively, the regulatory authorities may require further (phase IV) trials after approval, but these are often not completed in a timely manner, he says.

This results in a fractured regulatory process, where postmarketing surveillance falls short of the standards the agencies set for themselves.

This is exemplified by the case of rosiglitazone, which comes from a family of drugs with well documented side effects, he writes. However, postmarketing safety data seven years after regulatory approval consist of a patchwork of heterogeneous manufacturer sponsored trials, many of which are unpublished.

The system needs to be fixed, he says. This will require systematic rethinking of the existing regulatory and funding processes, and expediting changes currently in the pipeline.

In the meantime, doctors will need to revisit the indication for the drug on a case by case basis, bearing in mind that several alternatives are cheaper, supported by robust evidence, and now perhaps safer, he concludes.


'"/>




Related medicine news :

1. Australian Drug Regulators Call for Revamp On The Pharmaceutical Surveillance
2. Integrated Disease Surveillance Project Soon In The Country
3. Surveillance Program for Haemodialysis Reduces Infection
4. Estrogen Linked to Immune Surveillance in Breast Cancer
5. Low-risk Prostate Cancer Patients Prefer Surgery Over ‘active Surveillance
6. Time to Overhaul Australias Medicines Safety Surveillance System
7. Hong Kong, Guangdong Province To Increase Joint HIV/AIDS Surveillance
8. Early Warning System For Breast Cancer
9. Gene connected to Multi-System disorder discovered
10. Reviving the Immune System
11. Painkilling Patch As Effective As Intravenous Delivery Systems
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: